EC5026
Asset
Soluble epoxide hydrolase (sEH) inhibitor
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- Not known
- 7
- Indications
- 6
- Trials
- 1
- Developer
3 trials are still running. Trial NCT07694544 updated in its registry on Jul 10, 2026. clinicaltrials.gov
Indications
7Chronic kidney disease
Phase 1, Recruiting, NCT07694544, clinicaltrials.gov, Oct 31, 2026
Degenerative disc disease
Phase 1, Recruiting, NCT06438471, clinicaltrials.gov, Oct 31, 2026
Neuropathic pain
Phase 1, Recruiting, NCT06438471, clinicaltrials.gov, Oct 31, 2026
4 more
In the full profile
- Owner and partners1
- Trials6
- Competitors12
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.